Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juanito Uy

Endocrinology, Diabetes & Metabolism Muncie, IN Medical Doctor

NPI 1851531149 CMS profile 84624

5501 W Bethel Ave, Muncie, IN 47304

Open in the dashboard

General payments

$31,633

831 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Juanito Uy of Muncie, IN is reported in the CMS Open Payments database as having received $31,633 across 831 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,110 12
2024 General $2,216 127
2023 General $1,516 90
2022 General $2,112 143
2021 General $6,556 170
2020 General $5,145 112
2019 General $12,977 177

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juanito Uy
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Juanito Uy were reported at $1,110. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Juanito Uy Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $12,977 $494 $123–$2,253 $163
2020 $5,145 $335 $85–$1,841 $114
2021 $6,556 $398 $88–$1,981 $132
2022 $2,112 $364 $88–$1,568 $149
2023 $1,516 $420 $113–$1,614 $160
2024 $2,216 $440 $121–$1,646 $164
2025 $1,110 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $14,736 108 payments
  2. Merck Sharp & Dohme Corporation $6,689 86 payments
  3. Lilly USA, LLC $1,721 113 payments
  4. Novo Nordisk Inc $1,224 80 payments
  5. Abbott Laboratories $1,047 54 payments
  6. Amgen Inc. $696 26 payments
  7. Insulet Corporation $667 64 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $534 37 payments
  9. Xeris Pharmaceuticals, Inc. $462 31 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $409 26 payments
  11. Other $3,447 206 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,910 13 payments
  2. Food and Beverage $13,231 804 payments
  3. Travel and Lodging $276 7 payments
  4. Education $216 7 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $14,523 95 payments
  2. STEGLATRO $6,496 72 payments
  3. Ozempic $802 54 payments
  4. TRULICITY $760 60 payments
  5. JARDIANCE $686 55 payments
  6. STEGLUJAN $562 50 payments
  7. MOUNJARO $560 36 payments
  8. RYBELSUS $474 37 payments
  9. JANUVIA $450 47 payments
  10. Kerendia $409 26 payments
  11. Other $10,832 666 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

6,760

Median for Endocrinology: 1,959

Drug cost

$2,437,066

Median for Endocrinology: $890,201

Branded share of claims

59.7%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 364 $481,225
Ozempic Semaglutide Brand 213 $297,611
Farxiga Dapagliflozin Propanediol Brand 174 $183,974
Trulicity Dulaglutide Brand 106 $152,457
Jardiance Empagliflozin Brand 92 $117,795
Tresiba Flextouch U-100 Insulin Degludec Brand 158 $97,004
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 82 $92,917
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 74 $88,174
Synjardy Xr Empagliflozin/Metformin Hcl Brand 67 $77,452
Gvoke Hypopen 2-Pack Glucagon Brand 96 $64,412

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$230,496

Of which drugs: $33,269

Medicare patients

483

Average age 73

Services billed

10,285

338 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 51%
Arthritis 44%
Ischemic heart disease 42%
Chronic kidney disease 34%
Osteoporosis 32%
Depression 25%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 13 1,140 $23,370
Injection, gadobutrol, 0.1 ml A9585 Office 14 1,280 $279

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$222 92 —
TEPEZZA
$149 — —
AIRSUPRA
$146 — —
MOUNJARO
$144 364 —
FARXIGA
$136 174 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

831 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record